ARE YOUR PATIENTS AT INCREASED RISK?

Identify patients in your practice who have risk factors for shingles.

AGE

Starting at 50 years old, shingles risk sharply increases1

Incidence rate* of herpes zoster by age–United States1

Herpes zoster incidence rate by age in the United States chart

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles) in adults aged 50 years and older.

ADDITIONAL RISK FACTORS FOR SHINGLES

Patients ≥50 years old may have additional risk factors: certain comorbidities have been associated with an increased risk of shingles2,†

DIABETES

Pricked finger icon

24

%
INCREASED RISK of shingles in patients with DIABETES vs without

32 studies, pooled effect estimate:
RR: 1.24 (95% CI: 1.14-1.35)

ASTHMA

Inhaler icon

24

%
INCREASED RISK of shingles in patients with ASTHMA vs without

12 studies, pooled effect estimate:
RR: 1.24 (95% CI: 1.16-1.31)

COPD

Lungs icon

41

%
INCREASED RISK of shingles in patients with COPD vs without

12 studies, pooled effect estimate:
RR: 1.41 (95% CI: 1.28-1.55)

CHRONIC KIDNEY DISEASE

Kidneys icon

29

%
INCREASED RISK of shingles in patients with
CHRONIC KIDNEY DISEASE vs without

18 studies, pooled effect estimate:
RR: 1.29 (95% CI: 1.10-1.51)

CARDIOVASCULAR CONDITIONS

Heart shape icon

34

%
INCREASED RISK of shingles in patients with CARDIOVASCULAR CONDITIONS‡ vs without

16 studies, pooled effect estimate:
RR: 1.34 (95% CI: 1.17-1.54)

  • †

    Data from a meta-analysis assessing risk factors for HZ. The analysis included a total study population of 198,751,846 individuals, with 3,768,691 HZ cases across 88 studies (68 cohort and 20 case-control studies) from 1966 to 2019. The populations in these studies ranged from people aged 3 months to 104 years old.§ Eighteen risk factors were identified in the meta-analysis, note not all are presented here. Limitations included the following: most studies were observational and had a higher likelihood of bias; the majority of studies used administrative data, which is subject to miscoding, errors, and can vary between practitioners; finally, heterogeneity was high across studies. This list is not exhaustive and may not present all conditions associated with an increased risk of HZ.2

  • ‡

    Cardiovascular conditions included in each individual study in the meta-analysis varied by study and included heart disease, heart failure, hypertension, hyperlipidemia, stroke, atrial fibrillation/flutter, and other cardiovascular disease.2

  • §

    SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults ≥50 years old.

  • Cl=confidence interval; COPD=chronic obstructive pulmonary disease; HZ=herpes zoster; RR=relative risk.

SELECT CONDITIONS ASSOCIATED WITH PHN

In patients with shingles, certain comorbidities have been associated with increased odds of developing PHN3,‖

SHINGRIX is not indicated for the prevention of PHN or other herpes-zoster complications.4

DIABETES

Pricked finger icon

19

%
INCREASED ODDS in patients with DIABETES vs without

aOR: 1.19 (99% CI: 1.07-1.33)
Among 8492 patients with diabetes and shingles, 789 (9.3%) developed PHN

COPD

Lungs icon

53

%
INCREASED ODDS in patients with COPD vs without

aOR: 1.53 (99% CI: 1.35-1.72)
Among 5060 patients with COPD and shingles, 669 (13.2%) developed PHN.

ASTHMA

Inhaler icon

21

%
INCREASED ODDS in patients with ASTHMA vs without

aOR: 1.21 (99% CI: 1.06-1.37)
Among 8267 patients with asthma and shingles, 512 (6.2%) developed PHN.

  • ‖

    UK observational study using Clinical Practice Research Datalink, Among 119,413 patients with shingles (median age 61 years) diagnosed between January 2000 and December 2011, 5.8% developed PHN (defined as pain persisting for ≥90 days following shingles diagnosis). Odds ratios for PHN were modeled for select comorbidities and adjusted for age, sex, socioeconomic status, HIV, leukemia, lymphoma, myeloma, hematopoletic stem cell transplantation, other unspecified cellular immune deficiencies, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, COPD, asthma, CKD, depression, personality disorder, diabetes, recent cancer diagnosis, smoking, BMI category, site of zoster, antivirals, and immunosuppressive therapies.3

  • aOR=adjusted odds ratio; BMI=body mass index; HIV=human immunodeficiency virus; PHN=postherpetic neuralgia.

PATIENT PROFILES

Discover types of patients you may see in your practice who are at increased risk of shingles.

Click to expand content.

    WHAT YOU SAY MATTERS

     

    Strongly recommend SHINGRIX to help protect your appropriate patients who are at increased risk of shingles

    LEARN MORE

    Indication & Important Safety Info

    Indication

    Important Safety Information

    Indication

    SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

    • in adults aged 50 years and older.
    • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

    SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

    Important Safety Information

    • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
    • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
    • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
    • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
    • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
    • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
    • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
    • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
    • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
    • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
    • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

     

    Please see full Prescribing Information.

    To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
    1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

    References

    1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
    2. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: A meta-analysis. Open Forum Infect Dis. 2020;7(1):1-8.
    3. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology. 2016;87(1):94-102.
    4. Prescribing information for SHINGRIX.
    5. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl
1):S111-S118.
    6. Curran D, Matthews S, Boutry C, Lecrenier N, Cunningham AL, Schmader K. Natural history of herpes zoster in the placebo groups of three randomized phase III clinical trials. Infect Dis Ther. 2022;11(6):2265-2277.
    7. Shingles symptoms and complications. Centers for Disease Control and Prevention. Reviewed April 19, 2024. Accessed March 9, 2025. https://www.cdc.gov/shingles/signs-symptoms/index.html

      Questions About SHINGRIX?

      Call: 1-800-772-9292

      Available Monday - Friday

      8:30 am to 5:30 pm ET